JMS Co., Ltd. (7702) AI Stock Analysis

• Market Cap: ¥11.19B
• Dividend Yield: 3.78%
• Average Volume (3M): 36.54K
• Price to Earnings (P/E): 94.5
• Beta (1Y): 0.69
• Revenue Growth: 7.76%
• EPS Growth: -41.79%
• Country: JP
• Employees: 5,283
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -4.90
• Shares Outstanding: 24,733,465
• 10 Day Avg. Volume: 36,420
• 30 Day Avg. Volume: 36,536
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

JMS Co., Ltd. scores moderately due to strong revenue growth but is hindered by profitability challenges and an overvalued P/E ratio. The solid dividend yield offers some investor appeal, though the stock's technical position suggests caution. Stabilizing cash flows and improving profitability are essential for better scores.

JMS Co., Ltd. Business Overview & Revenue Model

Company Description

JMS Co., Ltd. (7702) is a Japan-based company primarily engaged in the manufacturing and sale of medical devices and related products. The company operates in the healthcare sector, focusing on developing innovative solutions for medical professionals and facilities. JMS Co., Ltd. offers a range of products, including infusion and transfusion systems, dialysis systems, and other medical equipment designed to enhance patient care and improve medical outcomes.

How the Company Makes Money

JMS Co., Ltd. generates revenue primarily through the sale of its medical devices and equipment to hospitals, clinics, and other healthcare facilities. The company's key revenue streams include the infusion and transfusion systems, which are essential for administering fluids and medications, and dialysis systems, which are crucial for patients with kidney failure. Additionally, JMS Co., Ltd. may engage in partnerships with medical institutions and research organizations to develop advanced healthcare solutions, thereby driving further sales and enhancing its market presence. The company also benefits from maintaining a strong distribution network to ensure the broad availability of its products in various regions.

JMS Co., Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
65.29B	63.74B	58.17B	57.58B	58.57B
	Gross Profit
14.09B	14.60B	14.27B	15.10B	15.64B
	EBIT
-268.00M	724.00M	980.00M	2.13B	2.31B
	EBITDA
4.08B	4.32B	4.34B	5.37B	5.47B
	Net Income Common Stockholders
-36.00M	281.00M	826.00M	1.74B	1.98B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
10.31B	6.33B	6.81B	6.22B	6.02B
	Total Assets
84.71B	74.41B	71.97B	69.08B	66.57B
	Total Debt
26.92B	19.75B	18.71B	18.50B	18.45B
	Net Debt
16.62B	13.42B	12.11B	12.53B	12.69B
	Total Liabilities
43.96B	35.71B	34.88B	34.09B	34.10B
	Stockholders Equity
40.57B	38.53B	36.96B	34.84B	32.34B
Cash Flow		Free Cash Flow
498.00M	-1.07B	1.14B	481.00M	263.00M
	Operating Cash Flow
3.14B	2.48B	4.40B	3.74B	3.56B
	Investing Cash Flow
-4.24B	-3.69B	-3.68B	-3.25B	-3.34B
	Financing Cash Flow
4.78B	525.00M	-499.00M	-535.00M	-1.19B

JMS Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 450.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7702, the sentiment is Negative. The current price of 450 is above the 20-day moving average (MA) of 447.65, below the 50-day MA of 456.86, and below the 200-day MA of 460.05, indicating a neutral trend. The MACD of 2.20 indicates Negative momentum. The RSI at 48.38 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7702.

JMS Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4543	78 Outperform	$4.18T	33.56	9.39%	0.96%	14.23%	26.82%
7701	70 Outperform	$1.09T	20.18	11.29%	1.57%	4.36%	-1.76%
7733	69 Neutral	$2.21T	26.92	12.71%	1.04%	7.60%	-66.30%
4549	66 Neutral	¥71.03B	35.29		2.40%	0.74%	-20.80%
7702	61 Neutral	¥11.19B	94.50		3.78%	7.76%	-41.79%
Sector *	52 Neutral	$5.17B	3.59	-42.19%	2.82%	15.05%	-0.04%
7746	47 Neutral	¥3.68B	82.73		―	14.87%	50.18%

JMS Co., Ltd. Corporate Events

JMS Co., Ltd. Reports Strong Q3 Financial Results

JMS Co., Ltd. has reported a significant improvement in its financial performance for the third quarter ending in December 2024. The company saw a 9.6% increase in net sales compared to the previous year, operating profit surged by 958.7%, and profit attributable to owners of the parent increased by 287.1%. These results indicate a robust recovery and potentially stronger market positioning, despite a decrease in comprehensive income by 37.4%.